MedPath
NMPA Approval

Ravulizumab Injection

国药准字SJ20250015

April 15, 2025

Drug Information

瑞利珠单抗注射液

伟立瑞

注射剂

300 mg(3 mL)/瓶

生物制品

April 15, 2025

April 14, 2030

Company Information

Applicant Company

Alexion Europe SAS

103-105 rue Anatole France, 92300 Levallois-Perret, France

Manufacturing Company

alexion pharma international operations limited, alexion athlone manufacturing facility (aamf)

Monksland Industrial Estate, Athlone, Co. Roscommon, N37 DH79, Ireland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

瑞利珠单抗注射液 - NMPA 批准文号 | MedPath